Randomized placebo-controlled trial of pantoprazole for daytime sleepiness in GERD and obstructive sleep disordered breathing
MV Suurna, J Welge, V Surdulescu… - … —Head and Neck …, 2008 - journals.sagepub.com
MV Suurna, J Welge, V Surdulescu, J Kushner, DL Steward
Otolaryngology—Head and Neck Surgery, 2008•journals.sagepub.comOBJECTIVE: To determine the efficacy of pantoprazole therapy for daytime somnolence,
psychomotor vigilance, and quality of life in patients with mild-moderate obstructive sleep
disordered breathing (OSDB) and gastroesophageal reflux disease (GERD). STUDY
DESIGN: Randomized, double-blind, placebo-controlled crossover trial. METHODS: Sixty
patients with daytime sleepiness, mildmoderate OSDB and GERD were randomly assigned
a 2-week treatment with pantoprazole 40 mg or placebo followed by a 2-week washout …
psychomotor vigilance, and quality of life in patients with mild-moderate obstructive sleep
disordered breathing (OSDB) and gastroesophageal reflux disease (GERD). STUDY
DESIGN: Randomized, double-blind, placebo-controlled crossover trial. METHODS: Sixty
patients with daytime sleepiness, mildmoderate OSDB and GERD were randomly assigned
a 2-week treatment with pantoprazole 40 mg or placebo followed by a 2-week washout …
OBJECTIVE: To determine the efficacy of pantoprazole therapy for daytime somnolence, psychomotor vigilance, and quality of life in patients with mild-moderate obstructive sleep disordered breathing (OSDB) and gastroesophageal reflux disease (GERD).
STUDY DESIGN: Randomized, double-blind, placebo-controlled crossover trial.
METHODS: Sixty patients with daytime sleepiness, mildmoderate OSDB and GERD were randomly assigned a 2-week treatment with pantoprazole 40 mg or placebo followed by a 2-week washout period and crossover respectively to 2-week treatment with placebo or pantoprazole. Outcomes included Epworth Sleepiness Score (ESS), sleep-related quality-of-life (FOSQ), and reaction time.
RESULTS: With pantoprazole, patients reported statistically significantly greater improvement of overall reflux symptoms (P = 0.0003) and in ESS (P = 0.04). A significant improvement was noted in FOSQ for both treatments with a trend toward greater improvement with pantoprazole (P = 0.058). No improvement in reaction times was observed.
CONCLUSION: Patients with coexistent GERD and OSDB noted significant improvement in daytime sleepiness after treatment with pantoprazole over placebo likely related to a reduction in nocturnal reflux-related arousals.
Sage Journals以上显示的是最相近的搜索结果。 查看全部搜索结果